New aspects concerning ulcerative colitis and colonic carcinoma: Analysis of levels of neuropeptides, neurotrophins, and TNFalpha/TNFreceptor in plasma and mucosa in parallel with histological evaluation of the intestine

Inflammatory Bowel Diseases

Volumn 14, Issue 10, 2008, Pages 1331-1340

  Johansson, Malin ^a   Jösson, Maria ^a   Norrgård, Örjan ^a   Forsgren, Sture ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Colitis; Mucosa; Neuropeptides; Neurotrophins; Plasma

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CORTICOSTEROID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROTROPHIN; NONSTEROID ANTIINFLAMMATORY AGENT; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE MUCOSA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS; BLOOD; CARCINOMA; CASE CONTROL STUDY; COLON TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY;

ADULT; AGED; CARCINOMA; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; MALE; NERVE GROWTH FACTORS; NEUROPEPTIDES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59749090144     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20487     Document Type: Article

References (55)

1. Maggi CA. The effects of tachykinins on inflammatory and immune cells. Regul Pept. 1997;70:75-90.
2. Koon HW, Pothoulakis C. Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann N Y Acad Sci. 2006;1088: 23-40.
3. Barde Y-A, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;15:49-53.
4. Levi-Montalcini R, Aloe L, Alleva E. A role for nerve growth factor in nervous, endocrine and immune systems. Prog Neuroendocrinimmunol. 1990;3:1-10.
5. Chao MV, Hempstead BL. p75 and Trk: a two-receptor system. Trends Neurosci. 1995;18:321-326.
6. Nockher WA, Renz H. Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation. Clin Chim Acta. 2005;352:49-74.
7. Gillardon F, Eschenfelder C, Rush RA, et al. Increase in neuronal Jun immunoreactivity and epidermal NGF levels following UV exposure of rat skin. Neuroreport. 1995;6:1322-1324.
8. Aalto K, Korhonen L, Lahdenne P, et al. Nerve growth factor in serum of children with systemic lupus erythematosus is correlated with disease activity. Cytokine. 2002;20:136-139.
9. Kim WK, Kan Y, Ganea D, et al. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci. 2000;20:3622-3630.
10. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology. 1996;111:1683-1699.
11. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:918-932.
12. Skaper SD, Pollock M, Facci L. Mast cells differentially express and release active high molecular weight neurotrophins. Brain Res Mol Brain Res. 2001;97:177-185.
13. Keränen U, Kiviluoto T, Jarvinen H, et al. Changes in substance P-immunoreactive innervation of human colon associated with ulcerative colitis. Dig Dis Sci. 1995;40:2250-2258.
14. Holzer P. Implications of tachykinins and calcitonin gene-related peptide in inflammatory bowel disease. Digestion. 1998;59:269-283.
15. Reinshagen M, Rohm H, Steinkamp M, et al. Protective role of neurotrophins in experimental inflammation of the rat gut. Gastroenterology. 2000;119:368-376.
16. Ma D, Wolvers D, Stanisz AM, et al. Interleukin-10 and nerve growth factor have reciprocal upregulatory effects on intestinal epithelial cells. Am J Physiol Regul Integr Comp Physiol. 2003; 284:R1323-1329.
17. Kimura M, Masuda T, Hiwatashi N, et al. Changes in neuropeptide-containing nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int. 1994;44:624-634.
18. Lee CMY, Kumar RK, Lubowski DZ, et al. Neuropeptides and nerve growth in inflammatory bowel disease: a quantitative immunohistochemical study. Dig Dis Sci. 2002;47:495-502.
19. Goldin E, Karmeli F, Selinger Z, et al. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci. 1989;34:754-757.
20. Renzi D, Mantellini P, Calabro A, et al. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis. Ital J Gastroenterol Hepatol. 1998;30:62-70.
21. Vandenabeele P, Declercq W, Beyaert R, et al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392-399.
22. Rothe J, Lesslauer W, Lötscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993; 364:798-802.
23. Bennett D. Neurotrophic factors: important regulators of nociceptive function. Neuroscientist. 2001;7:13-17.
24. Schulte-Herbrüggen O, Nassenstein C, Lommatzsch M, et al. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol. 2005; 160:204-209.
25. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science. 1987; 235:893-895.
26. Duffy LC, Zielezny MA, Ripenhoff-Talty M, et al. Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. Dig Dis Sci. 1989;34:1528-1535.
27. Todorovic V, Janic B, Koko V, et al. Colonic vasoactive intestinal polypeptide (VIP) in ulcerative colitis - a radioimmunoassay and immunohistochemical study. Hepatogastroenterology. 1996; 43:483-488.
28. Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007;13:727-732.
29. Lichstenstein GR. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis. 2001;7:89-93.
30. Reubi JC, Waser B, Schmassmann A, et al. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located? Int J Cancer. 1999;81:376-386.
31. Hejna M, Hamilton G, Brodowicz T, et al. Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. Anticancer Res. 2001;21:1183-1187.
32. Hang CH, Shi JX, Li JS, et al. Levels of vasoactive intestinal peptide, cholecystokinin and calcitonin gene-related peptide in plasma and jejunum of rats following traumatic brain injury and underlying significance in gastrointestinal dysfunction. World J Gastroenterol. 2004;10:875-880.
33. Metwali A, Blum AM, Elliott DE, et al. Cutting edge: hemokinin has substance P-like function and expression in inflammation. J Immunol. 2004;172:6528-6532.
34. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J. 2004;18:1325-1334.
35. Di Sebastiano P, Grossi L, Di Mola FF, et al. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci. 1999;44:439-444.
36. Stucchi AF, Shofer S, Leeman S, et al. NK-1 antagonist reduces colonic in.ammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol. 2000; 279:G1298-1306.
37. O'Connor TM, O'Connell J, O'Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167-180.
38. n Gomariz RP, Juarranz Y, Abad C, et al. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann N Y Acad Sci. 2006;1070: 51-74.
39. Johansson M, Norrgard O, Forsgren S. Study of expression patterns and levels of neurotrophins and neurotrophin receptors in ulcerative colitis. Inflamm Bowel Dis. 2007;13:398-409.
40. Fujimura H, Altar CA, Chen T, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost. 2002;87:728-734.
41. Namura K, Hasegawa G, Egawa M, et al. Relationship of serum brainderived neurotrophic factor level with other markers of disease severity in patients with atopic dermatitis. Clin Immunol. 2007;122:181-186.
42. Manni L, Lundeberg T, Fiorito S, et al. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheumatol. 2003;21:617-624.
43. Muangman P, Muffley LA, Anthony JP, et al. Nerve growth factor accelerates wound healing in diabetic mice. Wound Repair Regen. 2004;12:44-52.
44. Hanai H, Watanabe F, Yamada M, et al. Correlation of serum soluble TNF-alpha receptors I and II level with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004;99:1532-1538.
45. Dionne S, Ruemmele FM, Laberge S, et al. The effect of inflammation and of treatment on the production and release of TNFalpha by colonic explants in inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14:1435-1442.
46. Olsen T, Goll R, Husebekk A, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of in.ammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;12:1-9.
47. McCormack G, Moriarrt D, O'Donoghue DP, et al. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res. 2001;50:491-495.
48. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets. 2006;7:1043-1052.
49. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006;131:797-808.
50. Prasad S, Mathur A, Jaggi M, et al. Substance P analogs containing alpha,alpha-dialkylated amino acids with potent anticancer activity. J Pept Sci. 2007;13:544-548.
51. Azria D, Dorvillius M, Gourgou S, et al. Enhancement of radiation therapy by tumour necrosis factor alpha in human colon cancer using bispecific antibody. Int J Radiat Oncol Biol Phyas. 2003;55:1363-1373.
52. Albrethsen J, Bogebo R, Gammeltoft S, et al. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer. 2005;5:8.
53. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
54. Bowles WR, Sabino M, Harding-Rose C, et al. Nerve growth factor treatment enhances release of immunoreactive calcitonin gene-related peptide but not substance P from dorsal horn slices in rats. Neurosci Lett. 2004;363:239-242.
55. Bracci-Laudiero L, Aloe L, Buanne P, et al. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J Neuroimmunol. 2002;123:58-65.